北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心  > 期刊论文
学科主题: 临床医学
题名:
Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor
作者: Li, J.1; Gong, J. F.1; Wu, A. W.2; Shen, L.1
关键词: Adjuvant therapy ; Gastrointestinal stromal tumor ; Imatinib ; Recurrence-free survival ; c-KIT
刊名: EJSO
发表日期: 2011-04-01
DOI: 10.1016/j.ejso.2011.01.005
卷: 37, 期:4, 页:319-324
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Surgery
研究领域[WOS]: Oncology ; Surgery
关键词[WOS]: TERM-FOLLOW-UP ; RECURRENCE RATES ; EXPERIENCE ; MESYLATE ; PATTERNS ; GIST
英文摘要:

Aims; This study aims to determine whether adjuvant treatment with imatinib improves recurrence-free survival (RFS) in Chinese patients undergoing complete resection of localized primary gastrointestinal stromal tumor (GIST) compared with those not receiving adjuvant therapy. We also sought a correlation between c-KIT mutations and RFS.

Methods: Patients who had undergone complete tumor resection with intermediate or high risk of recurrence were enrolled in a single-center, non-randomized, prospective study. Patients either received adjuvant imatinib therapy (400 mg once-daily) for 3 years or did not. Mutation analyses of c-KIT were performed on available archival tumor samples.

Results: 105 patients were enrolled: 56 in the treatment group and 49 in the control group. Median follow-up was 45(43.1-46.9) months. RFS at 1, 2 and 3 years were higher in the treatment group than in the control group (100% vs. 90% at I year; 96% vs. 57% at 2 years; 89% versus 48% at 3 years, P < 0.001, HR = 0.188). Subgroup analyses showed that adjuvant therapy significantly decreased the risk of recurrence in patients whether at high risk or at intermediate risk compared with control patients (3-year RFS: 95% vs. 72%, in intermediate risk; 85% versus 31% in high risk; P < 0.001). In addition, imatinib adjuvant treatment decreased the risk of death (P = 0.039, HR = 0.254).

Conclusions: Adjuvant imatinib can improve 1-, 2- and 3-year RFS rates in patients at intermediate or high risk of recurrence after complete tumor resection. Clinical Trials Registration Number: ChiCTR-TCC-00000582 (C) 2011 Elsevier Ltd, All rights reserved.

语种: 英语
所属项目编号: 08-17
项目资助者: Beijing Cancer Hospital Foundation ; Novartis Oncology
WOS记录号: WOS:000289337400006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53893
Appears in Collections:北京大学临床肿瘤学院_胃肠肿瘤中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ, Sch Oncol,Beijing Canc Hosp & Inst,Dept GI Oncol, Beijing 100142, Peoples R China
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Gastrointestinal Surg, Beijing 100142, Peoples R China

Recommended Citation:
Li, J.,Gong, J. F.,Wu, A. W.,et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor[J]. EJSO,2011,37(4):319-324.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, J.]'s Articles
[Gong, J. F.]'s Articles
[Wu, A. W.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, J.]‘s Articles
[Gong, J. F.]‘s Articles
[Wu, A. W.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace